Rafik Hariri University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Mechref Lebanon (1999)

Organization Overview

First Clinical Trial
2009
NCT00855608
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Chronic Care Center and Rafik Hariri University Hospital, Beirut, Lebanon | Rafic Hariri University Hospital

Active Ingredients

Drugs in Phase 3 Trials (2)

prolycopene (1 trial)

vitamin d3 (1 trial)

Drugs in Phase 2 Trials (2)

aflibercept (zaltrap) (2 trials)

sodium 2,2-dimethylbutyrate (1 trial)

Drugs in Phase 1 Trials (1)

adalimumab (humira) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Avitaminosis (Phase 3)

beta-Thalassemia (Phase 2)

Choroidal Neovascularization (Phase 2)

Diabetic Retinopathy (Phase 2)

Insulin Resistance (Phase 3)

Macular Degeneration (Phase 2)

Macular Edema (Phase 2)

Metabolic Diseases (Phase 3)

Neovascularization, Pathologic (Phase 2)

Osteoporosis (Phase 3)

Pterygium (Phase 2)

Retinal Diseases (Phase 2)

Retinal Neovascularization (Phase 2)

Retinal Vein Occlusion (Phase 2)

Rickets (Phase 3)

Thalassemia (Phase 2)

Uveitis (Phase 1)

Vitamin D Deficiency (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 5